Tanvex Biopharma AI Stock Analysis
Want to see TW:6541 full AI Analyst Report?
Tanvex Biopharma (6541) AI Stock Analysis
Tanvex Biopharma
(TWSE:6541)
The overall score is constrained by a fundamental disconnect between soaring revenue and catastrophic gross margins, which is the most significant risk. While the company's strong balance sheet provides a temporary safety net, the stock's persistent technical downtrend and lack of profitability-based valuation support reinforce a cautious outlook. The primary challenge is the company's ability to transform its commercial success into a viable economic model before its cash reserves are depleted.
Tanvex Biopharma (6541) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 7.47B
- Dividend Yield
- ―
- Average Volume (3M)
- 432.45K
- Price to Earnings (P/E)
- -5.0
- Beta (1Y)
- 0.39
- Revenue Growth
- 207.37%
- EPS Growth
- 4.17%
- Country
- TW
- Employees
- 215
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Tanvex Biopharma Business Overview & Revenue Model
Company Description
Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medici...
Tanvex Biopharma Financial Statement Overview
Summary
Explosive 78% revenue growth signals commercial traction, but a deeply negative gross margin (-110%) and substantial net losses of TWD 1.5 billion highlight a fundamentally unprofitable core operation. A fortified balance sheet with low leverage (0.28x debt-to-equity) provides a cash runway, yet the company is burning cash to sell at a loss, creating a high-risk profile.
Income Statement
45NeutralBalance Sheet
72PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 657.56M | 400.97M | 34.68M | 61.41M | 22.40M | 5.41M |
| Gross Profit | -984.67M | -440.71M | 8.29M | 59.70M | -19.35M | 3.55M |
| EBITDA | -1.02B | -1.02B | -1.04B | -1.75B | -1.30B | -1.25B |
| Net Income | -1.47B | -1.50B | -1.38B | -2.14B | -1.64B | -1.54B |
Balance Sheet | ||||||
| Total Assets | 7.63B | 7.96B | 2.74B | 2.76B | 3.42B | 4.71B |
| Cash, Cash Equivalents and Short-Term Investments | 592.56M | 878.71M | 376.96M | 380.75M | 786.23M | 2.22B |
| Total Debt | 2.08B | 1.58B | 1.65B | 1.73B | 1.84B | 1.76B |
| Total Liabilities | 2.67B | 2.27B | 1.84B | 1.94B | 2.03B | 1.92B |
| Stockholders Equity | 4.97B | 5.69B | 893.31M | 821.11M | 1.39B | 2.79B |
Cash Flow | ||||||
| Free Cash Flow | -1.75B | -1.68B | -1.26B | -1.51B | -1.43B | -1.42B |
| Operating Cash Flow | -934.97M | -1.01B | -1.15B | -1.43B | -1.33B | -1.39B |
| Investing Cash Flow | -784.34M | 301.80M | -109.25M | -83.57M | -97.35M | -24.68M |
| Financing Cash Flow | 1.69B | 1.14B | 1.26B | 1.08B | -123.29M | 1.60B |
Tanvex Biopharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TW:6541, the sentiment is Negative. The current price of 28.15 is below the 20-day moving average (MA) of 29.32, below the 50-day MA of 30.87, and below the 200-day MA of 39.33, indicating a bearish trend. The MACD of -1.01 indicates Positive momentum. The RSI at 41.76 is Neutral, neither overbought nor oversold. The STOCH value of 65.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TW:6541.
Tanvex Biopharma Peers Comparison
Overall Rating
TW:416954Neutral- TW:654150Neutral
TW:414747Neutral
TW:654740Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4169 | 54Neutral | TWD 7.93B | -291.25 | ― | 0.27% | ― | ― |
| TW:6541 | 50Neutral | TWD 7.47B | -5.03 | -26.61% | ― | 207.37% | 4.17% |
| TW:4147 | 47Neutral | TWD 16.47B | -103.67 | ― | ― | 7.02% | 25.72% |
| TW:6547 | 40Underperform | TWD 16.94B | -409.93 | ― | ― | 44.37% | 78.11% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6541 | Tanvex Biopharma | 28.15 | -27.35 | -49.28% | |
| TW:4147 | TaiMed Biologics Inc. | 61.90 | -6.60 | -9.64% | |
| TW:4169 | TCM Biotech International Corp. | 116.50 | -63.27 | -35.20% | |
| TW:6547 | Medigen Vaccine Biologics Corp. | 46.35 | 8.95 | 23.93% | |
| TW:6586 | CHO Pharma, Inc. | 76.20 | 46.15 | 153.58% | |
| TW:6589 | EirGenix, Inc. | 51.70 | -30.20 | -36.87% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 08, 2026